Abstract
Prostate cancer is the most frequently diagnosed disease in American men today and the second leading cause of death among them. Transformation and progression towards malignancy in prostate cancer is dependant on the inability of the prostatic epithelial cells to undergo apoptosis rather than on the regulation of proliferation. Molecular targeting of inadequacies in this process of suppression of apoptosis could prove to be of great therapeutic importance for prostate cancer patients. Existence of tissue specific promoters to aid in the delivery of genes with therapeutic potential makes molecular therapy an attractive option. This review discusses salient features of molecules such as, Bcl-2, Bcl-XL, NF-kB, Akt, PTEN and Par-4 that play a significant role in the regulation of prostate cancer and focuses on the prospects of effectively utilizing their potential for the therapy of hormone-sensitive and hormone-resistant prostate cancer.
Keywords: par-4, prostate cancer, genes, apoptosis, molecular therapy
Current Pharmaceutical Design
Title: Molecular Therapy Intervention Prospects in Prostate Cancer
Volume: 10 Issue: 5
Author(s): Yashraj D. Rege and Vivek M. Rangnekar
Affiliation:
Keywords: par-4, prostate cancer, genes, apoptosis, molecular therapy
Abstract: Prostate cancer is the most frequently diagnosed disease in American men today and the second leading cause of death among them. Transformation and progression towards malignancy in prostate cancer is dependant on the inability of the prostatic epithelial cells to undergo apoptosis rather than on the regulation of proliferation. Molecular targeting of inadequacies in this process of suppression of apoptosis could prove to be of great therapeutic importance for prostate cancer patients. Existence of tissue specific promoters to aid in the delivery of genes with therapeutic potential makes molecular therapy an attractive option. This review discusses salient features of molecules such as, Bcl-2, Bcl-XL, NF-kB, Akt, PTEN and Par-4 that play a significant role in the regulation of prostate cancer and focuses on the prospects of effectively utilizing their potential for the therapy of hormone-sensitive and hormone-resistant prostate cancer.
Export Options
About this article
Cite this article as:
Rege D. Yashraj and Rangnekar M. Vivek, Molecular Therapy Intervention Prospects in Prostate Cancer, Current Pharmaceutical Design 2004; 10 (5) . https://dx.doi.org/10.2174/1381612043453234
DOI https://dx.doi.org/10.2174/1381612043453234 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/β -catenin Signaling
Current Cancer Drug Targets TNFα Modulation of Visceral and Spinal Sensory Processing
Current Pharmaceutical Design Mathematical Nanotoxicoproteomics: Quantitative Characterization of Effects of Multi-walled Carbon Nanotubes (MWCNT) and TiO2 Nanobelts (TiO2-NB) on Protein Expression Patterns in Human Intestinal Cells
Current Computer-Aided Drug Design Anticancer Chemodiversity of Ranunculaceae Medicinal Plants: Molecular Mechanisms and Functions
Current Genomics The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Recent Patents on Anti-Cancer Drug Discovery The Means to an End of Tumor Cell Resistance to Chemotherapeutic Drugs Targeting Thymidylate Synthase: Shoot the Messenger
Current Drug Targets Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry The Advance of Dendrimers - A Versatile Targeting Platform for Gene/Drug Delivery
Current Pharmaceutical Design Metformin Treatment Sensitizes Human Laryngeal Cancer Cell Line Hep- 2 to 5-Fluorouracil
Clinical Cancer Drugs Evaluating the Diagnostic and Chemotherapeutic Potential of Vancomycin- Derived Imaging Conjugates
Medicinal Chemistry The Influence of Ionizing Radiation on Exosome Composition, Secretion and Intercellular Communication
Protein & Peptide Letters New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Current Pharmaceutical Design Mirware: A MiRNA-mRNA Warehouse for Inference on Their Coordination
MicroRNA Cell Metabolism Under Microenvironmental Low Oxygen Tension Levels in Stemness, Proliferation and Pluripotency
Current Molecular Medicine Selectivity, Binding Affinity, and Ionization State of Matrix Metalloproteinase Inhibitors
Current Pharmaceutical Design New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets New Approaches to Photodynamic Therapy from Types I, II and III to Type IV Using One or More Photons
Anti-Cancer Agents in Medicinal Chemistry Marizomib, A Potent Second Generation Proteasome Inhibitor from Natural Origin
Anti-Cancer Agents in Medicinal Chemistry The Structural Features of α-Conotoxin Specifically Target Different Isoforms of Nicotinic Acetylcholine Receptors
Current Topics in Medicinal Chemistry Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma
Current Pharmaceutical Biotechnology